State Research Center of Virology and Biotechnology Vector, Koltsovo, Novosibirsk Region, 630559 Russia.
Mol Immunol. 2010 Apr;47(7-8):1507-15. doi: 10.1016/j.molimm.2010.01.020. Epub 2010 Feb 26.
Advances in defining HIV-1 CD8+ T cell epitopes and understanding endogenous MHC class I antigen processing enable the rational design of polyepitope vaccines for eliciting broadly targeted CD8+ T cell responses to HIV-1. Here we describe the construction and comparison of experimental DNA vaccines consisting of ten selected HLA-A2 epitopes from the major HIV-1 antigens Env, Gag, Pol, Nef, and Vpr. The immunogenicity of designed gene constructs was assessed after double DNA prime, single vaccinia virus boost immunization of HLA-A2 transgenic mice. We compared a number of parameters including different strategies for fusing ubiquitin to the polyepitope and including spacer sequences between epitopes to optimize proteasome liberation and TAP transport. It was demonstrated that the vaccine construct that induced in vitro the largest number of [peptide-MHC class I] complexes was also the most immunogenic in the animal experiments. This most immunogenic vaccine construct contained the N-terminal ubiquitin for targeting the polyepitope to the proteasome and included both proteasome liberation and TAP transport optimized spacer sequences that flanked the epitopes within the polyepitope construct. The immunogenicity of determinants was strictly related to their affinities for HLA-A2. Our finding supports the concept of rational vaccine design based on detailed knowledge of antigen processing.
在确定 HIV-1 CD8+ T 细胞表位和理解内源性 MHC 类 I 抗原加工方面的进展,使得能够合理设计多表位疫苗,以引发针对 HIV-1 的广泛靶向 CD8+ T 细胞反应。在这里,我们描述了由来自 HIV-1 主要抗原Env、Gag、Pol、Nef 和 Vpr 的十个选定 HLA-A2 表位组成的实验性 DNA 疫苗的构建和比较。在对 HLA-A2 转基因小鼠进行双重 DNA 初免和单次牛痘病毒加强免疫后,评估了设计的基因构建体的免疫原性。我们比较了许多参数,包括将泛素融合到多表位的不同策略,以及在表位之间包含间隔序列以优化蛋白酶体释放和 TAP 转运。结果表明,在体外诱导最多[肽-MHC 类 I]复合物的疫苗构建体在动物实验中也是最具免疫原性的。这种最具免疫原性的疫苗构建体包含靶向蛋白酶体的多表位的 N 端泛素,并且包含优化的蛋白酶体释放和 TAP 转运间隔序列,这些序列在多表位构建体中侧翼包被表位。决定簇的免疫原性与其与 HLA-A2 的亲和力严格相关。我们的发现支持基于抗原加工详细知识的合理疫苗设计概念。